Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 66(17): 12141-12162, 2023 09 14.
Artigo em Inglês | MEDLINE | ID: mdl-37646374

RESUMO

Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.


Assuntos
Cocaína , Transtornos Relacionados ao Uso de Substâncias , Humanos , Animais , Ratos , Serotonina , Benzotiazóis/farmacologia , Benzotiazóis/uso terapêutico , Encéfalo , Cocaína/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...